Opendata, web and dolomites

TISSUE

Tissue In Stroke Stratification Using e-ASPECTSTW

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TISSUE project word cloud

Explore the words cloud of the TISSUE project. It provides you a very rough idea of what is the project "TISSUE" about.

treatment    easily    standardised    neurological    restricted    prospective    commercial    acute    tomography    ncct    strategy    clinically    325    biomarker    financial    plan    indirect    arrive    budget    model    20    brainomix    brain    aspectstw    pricing    ischaemic    full    profits    economic    tissue    feasibility    thrombolysis    units    25    reaching    projections    imaging    employment    output    competition    socioeconomic    market    annual    device    additional    clinical    leaders    cerebrovascular    contrast    benefit    intravenous    hospital    nccts    position    stroke    receive    direct    stratification    health    unknown    disorders    size    untreated    275    biomarkers    business    time    burden    hospitals    euros    000    patients    trial    worldwide    medical    accessible    benefits    software    automated    symptom    centre    approved    scans    250    fast    onset    eligible    validate    ltd    version    participating    hours    revenues    computed    global   

Project "TISSUE" data sheet

The following table provides information about the project.

Coordinator
BRAINOMIX LIMITED 

Organization address
address: SUFFOLK HOUSE SUITES 11-14 263 BANBURY ROAD
city: OXFORD
postcode: OX2 7HN
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website https://ec.europa.eu/research/participants/portal/desktop/en/opportunities/h2020/topics/2594-phc-12-2014.html
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2014
 Duration (year-month-day) from 2014-10-01   to  2015-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BRAINOMIX LIMITED UK (OXFORD) coordinator 50˙000.00

Map

 Project objective

Stroke is a burden with far reaching socioeconomic impact. The only approved treatment in ischaemic stroke is intravenous thrombolysis, which is restricted to 4.5 hours after symptom onset and currently, only 20% of all stroke cases are eligible to receive it. An additional 25% remain untreated because they arrive at the hospital with unknown time of onset.

The objective of the “Tissue In Stroke Stratification Using e-ASPECTSTW” (TISSUE) proposal is to clinically validate the ASPECTS method and its automated version, the medical device software e-ASPECTSTW, as an imaging biomarker on Non-Contrast Computed Tomography (NCCT) brain scans for identifying ischaemic stroke patients with unknown time of onset who can benefit from thrombolysis.

e-ASPECTSTW addresses the growing worldwide market of 3,250,000 patients (275,000 patients in Europe) every year having a stroke with unknown time of onset. The annual global market size of e-ASPECTSTW is 325,000,000 Euros. Users of e-ASPECTSTW will be hospitals worldwide that provide acute stroke treatment. e-ASPECTSTW will be integrated in existing clinical pathways offering a standardised, fast, reliable and easily accessible assessment of NCCTs. This will increase the uptake of thrombolysis and provide significant economic benefits to hospitals and the health system. The commercial exploitation of the project results will enhance the growth of Brainomix Ltd leading to increased revenues, profits, employment and will position Brainomix as leaders in imaging biomarkers for neurological and cerebrovascular disorders.

The output of the feasibility study will be a full business plan, including an analysis of the European and global stroke market, an analysis of direct, indirect and potential competition; a detailed business model and pricing strategy as well as financial projections and a detailed design and budget of the prospective multi-centre clinical trial including the participating stroke units.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TISSUE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TISSUE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

AutoCRAT (2020)

Automated Cellular Robot-Assisted Technologies for translation of discovery-led research in Osteoarthritis

Read More